(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Vyvgart Hytrulo is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The ADHERE trial was a multicenter, randomized, ...

for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at ...

Dianthus Therapeutics is advancing treatments for autoimmune diseases. Read why DNTH stock is receiving Buy ratings and price ...

JMP Securities analyst Jason Butler raised the firm’s price target on Argenx (ARGX) to $696 from $606 and keeps an Outperform rating on the ...

Soleo Health, a leader and national provider of complex specialty pharmacy services, announced Jan. 7 the opening of its new ...

Kain Science passes technical evaluation for KOSDAQ special listing Kain Science moves closer to KOSDAQ listing after ...

Analysts have recently evaluated KORU Medical Systems and provided 12-month price targets. The average target is $4.7, ...

JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of ...

The Soleo Health Denver AIS, located at 9250 East Costilla Avenue, Suite 440, Greenwood Village, CO 80112, 303.968.1915, is just minutes from major medical centers and easily accessible to major ...